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Stroke prevention: recent achievements and new
challenges
Abstract
Stroke remains a major health problem despite the great efforts made
worldwide to fight against it. Despite therapeutic achievements to treat
ischemic stroke patients in stroke units with tissue plasminogen activator
(tPA), prevention remains the most powerful strategy to cure this complex
disease. Stroke is a heterogeneous and multi-factorial disease caused by the
combination of vascular risk factors, environment, and genetic factors. These
risk factors can be subdivided into non-modifiable (age, sex, race-ethnicity,
genetic variations and predispositions) and modifiable (hypertension, dia-
betes, dyslipidemia, atrial fibrillation, carotid artery stenosis, smoking, poor
diet, physical inactivity and obesity). The metabolic syndrome, a cluster of
metabolic risk factors within an individual, has been recognized as and
important factor associated with an increased risk of stroke. Recently, a great
emphasis has been given to the investigations of genetic factors and stroke risk,
which may lead to the discovery of new biomarkers for prevention, diagnosis
and to the alternative strategies for stroke treatment. In this review we sought
to discuss the main risk factors for stroke and the current strategies of stroke
prevention.
INTRODUCTION
Stroke is a devastating disease with enormous personal, social andeconomic consequences. It is the second leading cause of death
worldwide and its burden is expected to increase as the population ages
and the incidence of the disease’s risk factors such as hypertension and
diabetes increase across the globe (1) Certain therapeutic strategies
such as stroke unit care and treatments including tissue plasminogen
activator (tPA) have been developed to treat acute stroke more effecti-
vely and lessen the amount of disability that the disease carries. How-
ever, these modalities are not available universally in developed coun-
tries and scarcely at all in developing ones, with t-PA utilization of less
than 1 in 10 patients where it is even available (2). Moreover, more than
75% of strokes each year are first-ever strokes, making the primary
prevention of utmost importance (3). Although stroke is a clinical
diagnosis with many sub-classifications and distinct yet sometime over-
lapping entities, the identity of the risk factors is well known with many
treatments readily available. The disease can be controlled, and perhaps
largely prevented, thus achieving a sizeable public health benefit. Suc-
cessful implementation of the preventive tools at our disposal remains a
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overview
The stroke risk factors can be subdivided into non-
-modifiable (age, sex, race-ethnicity, genetic variations
and predispositions) and modifiable (hypertension, dia-
betes, dyslipidemia, atrial fibrillation, carotid artery ste-
nosis, smoking, poor diet, physical inactivity and obesity)
(Table 1). An individual risk factor may contribute to
each subclassification of stroke differently, and there is a
large overlap or risk factors with cardiovascular and peri-
pheral vascular disease. This review will focus on the
current updates of the management of traditional and
novel risk factors in stroke prevention, the challenges of
successful management and future directions for research
and further therapeutic successes. Potentially modifiable
stroke risk factors such as sleep apnea, alcohol, drug
abuse, and hyperhomocysteinemia are discussed as is the
use of antiplatelet therapy for primary stroke prevention.
Hypertension
Hypertension is the most important modifiable risk
factor for stroke. Several studies have concluded that it
accounts for more than the third of the stroke burden and
maybe as much as half of all strokes (4, 5). The control of
high blood pressure (BP) contributes to prevention of
first strokes but also of renal and heart failure (6) and
possibly cognitive decline (7, 8) and frank dementia (9).
It has been shown that for every 20-mmHg increase in
systolic and 10-mmHg increase in diastolic BP greater
than 115/75 mmHg, there is a 2-fold increase in morta-
lity associated with stroke and coronary disease (10).
Conversely, a 10 mmHg reduction in systolic BP has
been shown to lower the stroke risk by about a third in
primary and secondary stroke prevention (11–13). These
benefits also extend to the elderly, where in one study, a
36% reduction was found in the incidence of stroke for
patients over the age of 60 who were treated with a
thiazide diuretic with or without a beta-blocker (14). A
more recent study of patients over the age of 80 showed
that lowering the mean systolic BP by 15 mmHg and
mean diastolic BP by 6.1 mmHg lowered the rate of fatal
strokes by 39% after 2 years of treatment (15). A meta-
-analysis of 31 trials, with 190,606 participants, showed
the benefits for educed BP in both younger (<65 years)
and older (=65 years), implying that the benefits from
better pressure control can be reaped at any age (16). A
more intensive regimen appears to be more beneficial: in
the ACCORD, a 5,000 patient study of those with dia-
betes, the patients who were in a more intense BP lower-
ing group < 120, had a significantly lower risk of stroke
after a follow-up of 4.7 years compares to those with a BP
lowering goal of <140 (17). While the BP lowering has
reduced the risk for all stroke subtypes, these findings are
more pronounced for hemorrhagic strokes.
A comprehensive evidence-based approach to treat-
ment of hypertension is provided by the Seventh Report
of the Joint National Committee on Prevention, Detec-
tion, Evaluation, and Treatment of High Blood Pressure
(JNC 7) (18). The JNC 7 treatment recommendations
are provided in Table 1. The release of JNC 8 document
is expected by the end of 2012 (19). Several categories of
antihypertensive medications such as thiazide diuretics,
b-adrenergic receptor blockers, angiotensin-converting
enzyme inhibitors (ACEIs), angiotensin receptor blockers
(ARBs), and calcium channel blockers (CCBs) have been
shown to reduce the risk of stroke in patients who are
hypertensive (20–23). Thiazide-type diuretics were origi-
nally recommended as the preferred initial drugs of treat-
ment for most patients (24). A more recent meta-analyses,
however, has shown that with a few exceptions (beta-
-blockers after a recent myocardial infarction (MI) and
additional benefits of CCBs) all the different classes of
BP-lowering medications produced a similar reduction
in the incidence of stroke and CVD for a given reduction
in BP (25).
BP control can be achieved in a vast majority of pa-
tients, with most requiring combination therapies and
often more than 2 antihypertensive medications (26).
Unfortunately, BP is controlled in less than a quarter of
the hypertensive population worldwide (27). Given the
importance of hypertension as a stroke risk factor, and
the abundance of effective treatments available, provid-
ing effective population-wide but patient-specific inter-
ventions remains a major public health care challenge.
Diabetes
Diabetes is an established risk factor for all vascular
events in general and ischemic stroke (IS) in particular.
Individuals with type 2 diabetes also have an increased
vulnerability to atherosclerosis and an increased pre-
valence of hypertension, hyperlipidemia and obesity. Car-
diovascular disease (CVD) and IS develops earlier in
patients with diabetes, and strokes in patients with dia-
betes tend to have a heavier morbidity burden. American
Diabetes Association recommends a multi-faceted ap-
proach to optimal health in diabetics; not only controll-
ing the blood glucose, but also aggressive treatment of
associated cardiovascular risk factors, with lower targets
than for the general population (28). Surprisingly, recent
studies have shown that aggressive treatment of blood
glucose was very effective in preventing mircovascular
complications of diabetes, but had no statistical effect on re-
duction of macrovascular events, including stroke (29–31).
However, the evidence that a multifactorial approach
(reduced intake of dietary fat, light to moderate exercise,
cessation of smoking) reduces stroke and cardiovascular
risk in type-2 diabetics is supported by subgroup analyses
of diabetic patients in large clinical trials. In the UK
prospective Diabetes Study Group, comparing a tight BP
control group (mean BP 144/82 mmHg) vs less stringent
control group (mean BP 154/87 mmHg) resulted in a
reduction of 44% of fatal and non-fatal stroke between
the two groups (32). Another study found that adding a
statin to existing treatments in high risk patients resulted
in a 24% reduction in strokes (33). The Collaborative
Atorvastatin Diabetes Study (CARDS) evaluated statin
therapy in diabetic patients as a primary prevention of
vascular events. A total of 2838 people with type 2 dia-
betes were enrolled, and the trial was stopped early due to
its efficacy points being met: 37% reduction the primary
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vascular events in general, and a 48% reduction of strokes
in particular (34).
Good glycemic control involves appropriate insulin
therapy and professional dietary and lifestyle therapy for
type 1 diabetics and weight loss, increased physical acti-
vity and, if need be, oral and injectable hypoglycemic
agents for type 2 diabetics. Treatment of adults with dia-
betes, especially those with additional risk factors, with a
statin to lower the risk of a first stroke is recommended
(35). Studies have shown that a multi-faceted approach
to controlling diabetes and concomitant risk factors leads to
significant reduction in cardiovascular events and stroke.
Dyslipidemia
Many epidemiologic studies found no consistent
relationship between cholesterol levels and overall stroke
risks. However, there is evidence that there is a positive
correlation between total and low density lipoprotein
(LDL) cholesterol levels and the risk of stroke (36, 37).
Conversely, high density lipoprotein (HDL) cholesterol
levels have been associated with reduced risk of IS across
many sub-populations (38, 39). Moreover, in high risk
patients, lowering cholesterol with statins (HMG-CoA
reductase inhibitors) has been shown to significantly
reduce the risk of transient ischemic attack (TIA) or
non-cardioembolic stroke (40, 41). Several meta-analysis
have shown that lowering the LDL cholesterol by 1.0
mmol/L reduced the risk of IS by about 20% (42, 43).
The beneficial role of statins for primary and secondary
stroke risk reduction for those with high risk for CVD
risk has been documented (34, 44, 45). It has estimated
that statins prevent 9 strokes per 1000 high risk patients
or in those with coronary heart disease (CHD) treated
over the period of 5 years. Earlier concerns of statins
increasing the risk of hemorrhagic stroke (40) have not
been substantiated by a recent meta-analysis, (46) alt-
hough the topic is still under debate (47) and caution
should be exercised.
The benefit of rosuvastatin in cutting the risk of myo-
cardial infarction (MI) in half in those patients who were
apparently healthy but had elevated levels of C-reactive
protein (CRP) hints at the many pleotropic effects of
statins (48). Although this class of drugs is very well
studied, the way it protects the brain and the heart is not
entirely clear. It may decrease platelet aggregation, stabi-
lize plaques, lower BP and reduce inflammation. There
has been further speculation that they may have neuro-
protective properties, improve endothelium function,
decrease smooth muscle proliferation and increase the
number of circulating endothelial progenitor cells (49).
Intriguing results have shown statins to increase nitric
oxide (NO) production and P-selectin expression and
up-regulate tissue-type plasminogen-activator (50). It is
unclear if statins lower the risk of stroke by lowering the
LDL, or by any of the above and maybe yet-unknown
mechanisms. Other surrogate markers for artherosclero-
sis, such as carotid intima-media thickness (cIMT), may
prove to be useful in monitoring the progression of and
treatments against stroke and other vascular diseases (51).
Non-statin lipid-modifying therapies may also offer
stroke protection, although the studies are less equivocal.
Niacin treatment has been shown to increase HDL as
part of a combination therapy (52, 53) Evidence has been
mixed on the exetimibe/statin combinations and if they
are superior to mono-statin therapies. Fibrates have been
shown to decrease the risk of coronary events and retino-
pathy, but not that of IS (54). Fibrates, Niacin, exetimibe
and omega-3 fatty acids each regulate serum lipids by
different mechanisms and a combination therapy may be
the final answer in achieving desired lipid control.
National Cholesterol Education Program III (NCEP
ATP III) guidelines for the management of patients who
have not had a stroke and who have elevated total cho-
lesterol or elevated non–HDL cholesterol in the presence
of hypertriglyceridemia have been endorsed in the US
(Table 1) (55). The updated clinical guidelines for cho-
lesterol testing and management (ATPIV) from the Ex-
pert Panel on Detection, Evaluation, and Treatment of
High Blood Cholesterol in Adults are expected to be
published by the end of 2012 (56).
Although the benefits of statin therapy outweigh the
low risk of serious side effects, there are still some popu-
lations for which more data on the safety of lipid-lower-
ing therapies are needed to clarify the risk associated with
the effect of treatment, especially for older persons (>70
years of age) and women. More clinical trials and further
research for optimal lipid-lowering strategies are needed
as the complex relationship between dyslipidemia, athe-
rosclerosis, stroke and CVD exists and has not been
entirely elucidated.
Metabolic Syndrome
Metabolic Syndrome (MetS) is defined by a cluster of
interconnected factors that increase the risk of athero-
sclerosis, CVD, stroke, and diabetes mellitus type 2. Its
components are dyslipidemia (elevated triglycerides and
apolipoprotein B (apoB)-containing lipoproteins, and
HDL), elevation of arterial BP and impaired glucose
homeostasis, with abdominal obesity and/or insulin re-
sistance (IR) (55, 57). More recently, other factors such as
proinflammatory state, oxidative stress, and non-alcoho-
lic fatty liver disease have been suggested to play an
important role in MetS, making its definition even more
complex. To date the most used definition for MetS is the
NCEP ATP III definition (55). All the components of
MetS are involved in conferring risk of stroke and CVD.
The adjusted hazard ratio (HR) for incident IS associat-
ed with MetS ranges between 2.1 and 2.5 in prospective
studies, and a HR as high as 5.2 has been reported
(58–60). In a cohort of 14,284 patients, patients with
MetS but without diabetes exhibited a 1.49-fold increas-
ed risk of IS or TIA, whereas those with frank diabetes
had a 2.29-fold increased risk (58). The relative odds for
IS or TIA, associated with presence of MetS, were 1.39 in
men and 2.10 in women. In NOMAS, a significant as-
sociation between the MetS and IS risk was reported to
be independent of other confounding factors including
age, education, physical activity, alcohol use, and current
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TABLE 1
Stroke risk factors and treatment recommendations.
STROKE RISK FACTORS CURRENT RECOMMENDATIONS
Non-modifiable stroke risk factors
Age, Sex, Race-ethnicity
Genetic variations and predisposition






Drugs for the compelling indication
Drugs for the compelling indication. Other drugs (diuretics, ACEIs,
ARBs, b-blockers, calcium channel blockers) as needed.
Drugs for the compelling indication and other drugs as needed
* Lifestyle modifications




0–1 CHD risk factor*
2 CHD risk factors and 1y
CHD risk <20%
=2 CHD risk factors and
10-y CHD risk 10–20%
CHD or CHD risk
equivalent (10-y risk >20%)
CHD or CHD risk
equivalent (10-y risk >20%)
Non-HDL-C in persons with
triglycerides =200 mg/dL
Low HDL-C
Diet, weight loss, physical activity; Drug therapy if LDL-C remains =
190 mg/dL. If LDL-C 160–189 mg/dL drug therapy optional
Diet, weight loss, physical activity; Drug therapy if LDL-C =160
mg/dL
Diet, weight loss, physical activity; Drug therapy if LDL-C remains
=130 mg/dL (or =100 mg/dL)
Diet, weight loss, physical activity; Drug therapy if LDL-C is =130
mg/dL and optional for LDL-C 70–129 mg/dL
Diet, weight loss, physical activity; Drug therapy if LDL-C is =130
mg/dL and optional for LDL-C 70–129 mg/dL
Same as LDL-C with goal 30 mg/dL higher
Weight loss, physical activity. Consider niacin or a fibrate in high-risk
individuals with HDL-C <40 mg/dL
Metabolic Syndrome Control vascular risk factors (components of Metabolic Syndrome)
*Lifestyle modifications






Anticoagulation and antithrombotic therapies
Surgery
* Lifestyle modifications
Carotid Artery Stenosis Endarterectomy may be considered in selected patients with >60% stenosis without occlusion.
Careful patient selection should be guided by individual factors including comorbid conditions, life
expectancy and patient preference.
Smoking Counseling, nicotine replacement, varenicline, and formal programs are recommended.
Poor Diet A diet containing 5 servings of fruits and vegetables per day may reduce the risk of stroke
Obesity Weight reduction
Physical Inactivity Moderate exercise (e.g., brisk walking, jogging, cycling, or other aerobic activity).
Potentially modifiable stroke risk factors
Sleep Apnea Overnight sleep study in patients with snoring, excessive daytime sleepiness, body mass index over 30
and drug-resistant hypertension. CPAP treatment
Alcohol No more than 2 drinks/day for men, and no more than 1 drink/day for women
Drug Abuse A history of substance abuse should be part of health evaluation
Hyperhomocysteinemia Daily intake of folate (400 µg/d), B6 (1.7 mg/d), and B12 (2.4 µg/d) by consumption of vegetables,
fruits, legumes, meats, fish, and fortified grains and cereals
*Lifestyle modifications are encouraged for all and include (1) weight reduction if overweight, (2) limitation of ethyl alcohol intake, (3) increased aerobic
physical activity (30–45 minutes daily), (4) reduction of sodium intake (<2.34 g), (5) maintenance of adequate dietary potassium (>120 mmol/d), (6)
smoking cessation, and (7) DASH diet (rich in fruit, vegetables, and low-fat dairy products and
smoking (61). The prevalence of MetS in NOMAS was
49%, and differed by sex (39% in men, 55% in women,
p<0.0001) as well as race-ethnicity (56% in Hispanics,
41% in blacks, and 39% in whites, p<0.0001). Inte-
resting, the effect of the MetS on stroke risk was greater
among women (HR=2.0; 95% CI, 1.3 to 3.1) than men
(HR=1.1; 95% CI, 0.6 to 1.9) and among Hispanics
(HR=2.0; 95% CI, 1.2 to 3.4) compared to blacks and
whites.
MetS is also associated with subclinical atherosclero-
sis. In NOMAS, we have shown an independent associa-
tion between MetS and ultrasonographic subclinical mea-
sures of atherosclerosis including carotid plaque and
carotid stiffness (63, 64). Therefore, an early identifica-
tion of people at high risk for vascular accidents by eva-
luating subclinical markers of atherosclerosis is prudent
in order to initiate preventive treatments.
Although the existence of MetS as a separate entity
has been recently questioned, individuals with a cluster
of the risk factors that comprise MetS should be ag-
gressively treated for hypertension, dyslipidemia and dia-
betes. Patients with MetS have a greater risk of stroke and
other vascular diseases and therefore »a major break-
through related to the concept of the MetS is the recognition
of the high cardiovascular risk in subjects with a cluster of
mild abnormalities or with a cluster of abnormalities that
are not regarded as driving forces in CVD« (62).
Atrial Fibrillation
Atrial fibrillation (AF) is a common cardiac arrhyth-
mia and a frequent cause of cardioembolic strokes. It
account for up to 20% of all IS, and the presence of AF
independently increases the risk of these events by up to
5-fold (65). The incidence of AF increases with age, with
as many as 10% of the population experiencing AF in
their 80s (66) and the number of affected patients may
reach 12 million just in the U.S. by 2050 (67). Despite its
increasing burden, AF is also arguably one of the best-
-studied causes of stroke with dozens of randomized
trials and well-established evidence-based recommen-
dations regarding effective medical treatments.
Stroke risk stratification models have been developed
and validated. CHADS2 (Congestive heart failure, Hy-
pertension, Age, Diabetes, Stroke/TIA) is the most well-
-known stratification system (68). It subdivides patients
based on the independent predictors of stroke in those
with AF and offers validated recommendations of anti-
coagulation vs antithrombotics therapy based on the scale
scores. Several other models for predicting stroke risk,
(such as the National Institute for Health and Clinical
Excellence (NICE) guidelines [69] and CHADS2-VASc
[70]) and bleeding risk (HAS-BLED (71) have since
been developed.
Anticoagulation and antithrombotic therapies remain
the main agents for stroke preventions for those with AF.
Warfarin is the most commonly used anticoagulant, that is
cheap and exceedingly effective in preventing IS: a recent
meta-analysis showed a reduced risk of cardioembolic
stroke of 64% for those on warfarin vs only 22% for those
on aspirin. Warfarin also provides an almost 40% relative
risk reduction compared to anti-platelet therapies (72).
Despite its effectiveness, this anticoaguant has several
limitations (narrow therapeutic window, many drug and
diet interactions, frequent and inconvenient monitor-
ing) and has been under-utilized (73, 74). It is difficult to
keep in range with only two-thirds of patients in clinical
trials and little more than half in the community setting
being in the therapeutic range (75, 76).
Given the utilization gap for warfarin, several novel
oral anticoagulants that are just as effective, have a better
side effect profile and require less monitoring have been
developed, tested and approved. The three novel oral
anticoagulants that have shown the most promising ef-
fectiveness and safety data are Dabigatran (77), Rivaro-
xaban (78), and Apixaban (79). They all exhibit a stable
pharmacological profile, very few drug-drug interactions
and are almost unaffected by the patients’ diet. Very few
patients (renal impairment or body weight extremes)
require regular monitoring. They appear to be as effec-
tive, and in some cases superior to warfarin, with a much
improved side effect profile. Less intracranial bleeding,
arguable the most feared complication of coumadin, has
been observed. These new agents will likely completely
change how we treat patients with AF and lead to a
greater reduction of cardioembolic strokes in the future.
Other Cardiac Conditions
Other times of cardiac disease that contribute to the
risk of IS include congestive heart failure (CHF), MI,
dialted cardiomyopathy, valvular heart disease (eg. mecha-
nical valves, mitral valve prolapse, etc) and congenital
defects [eg. patent foramen ovale (PFO), atrial septal
defect and aneurysm]. All patients with prosthetic valves
should be anti-coagulated (80). The rate of thrombo-
embolism is reduced by half with antiplatelet therapy
and by more than 75% with anticoagulation (81). Pa-
tients with CHF, have a higher risk of stroke (2–3 fold)
and are more likely to incur more significant stroke-
-related morbidity and mortality compared to those with-
out heart failure (82). Low ejection fraction (especially
below <30%) has been identified as a risk factor for
stroke, (83) however, studies on the best treatments for
this condition remain inconclusive. Presence of aortic
arch atheroma is associated with increased risk of IS (84).
Congenital defects, while relatively common, contribute
to the burden of stroke only in relatively specific circum-
stances. Most of these cardiac abnormalities and the po-
tential thrombi that they produce require all and careful
cardiac workup for detection, including a transthoracic
and transesophageal echocardiography, and extensive
cardiac monitoring with telemetry and often a more
protracted outpatient cardiac event recorder.
Asymptomatic Cardiac Stenosis
Carotid stenosis of 50% or greater can be found in
about 5–10% of people who are older than 65, and the
prevalence of a severe asymptomatic carotid stenosis has
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been found in 3.1% of the population (85, 86). Data from
observational studies and clinical trials indicate an an-
nual risk of stroke attributable to extracranial carotid to
have increased with the degree of stenosis (from less than
1% a year for a <80% stenosis to 4.8% per year for a
>90% occlusive lesion). In Asymptomatic Carotid Athe-
rosclerosis Study (ACAS), patients with asymptomatic
carotid artery stenosis of =60% were randomized to
carotid endarterectomy (CEA) or best medical mana-
gement, with the results showing the primary outcome of
ispilateral stroke, death or any perioperative stroke to be
5.1% for surgical candidate and 11% for patients treated
medically over 5 years, with an absolute risk reduction of
1% a year (87). Asymptomatic Carotid Surgery Trial
(ACST) randomized asymptomatic patients with signi-
ficant carotid stenosis (>60%) for immediate surgery vs.
medical management and were followed for a mean of
3.4 years (88). The study found the overall 5-year risk of
stroke or perioperative death to be 11.8% with deferred
surgery and 6.4% with immediate endarterectomy. In the
subgroup analysis, CEA appeared to be more beneficial
for men than women, and in younger patients more than
older individuals. A more recent study, Asymptomatic
Carotid Embolic Study (ACES), of patients who were
followed for 2 years and had a asymptomatic carotid
stenosis of at least 70% and were noted to have embolic
signals found to have a significantly higher risk of ipsi-
lateralstroke compared to those without any emboli, sug-
gesting the detection of embolization on transcranial
Doppler may be used for additional risk stratification
(89). The benefit of endarterectomy in asymptomatic
stenosis is dependent on the surgical risk. Trials of ca-
rotid surgery for asymptomatic carotid disease reduced
the risk of stroke by about 1% per annum, while the
perioperative stroke rate is 3%. Medical management
should be offered to most patients and only high-volume
centers with complication rate of =3% should contem-
plate the surgical procedure. It appears that men and
those with life expectancy of more than 5 years will derive
the most benefit in appropriate centers (90). Most physi-
cians, however, are not aware of CEA complication rates
at their institutions. The best medical management has
been evolving with wider use of antiplatelet agents, blood
pressure and lipid lowering drugs, reducing the risk of
stroke to 1% (91, 92). and therefore the above relative
benefit of CEA may need to be recalibrated.
Carotid angioplasty and stenting (CAS) was deve-
loped as a less invasive procedure compared to carotid
endarterectomy. It has emerged as an alternative for pa-
tients who are high surgical risks, have many medical
comorbidities, previous neck radiation, contralateral laryn-
geal nerve palsy or surgically-suboptimal anatomy. Since
its invention over 20 years ago, the technique has evolved
to more sophisticated and intricate stents, embolic pro-
tection devices and increasing operator experience. The
Stenting and Angioplasty with Protection in Patient at
High Risk of Endarterectomy (SAPPHIRE) Trial shows
that stenting was non-inferior to CEA among high-risk
surgical patients (93). The comparison of CEA and CAS
has been extensively studied, often producing contra-
dictory and confusing results. On one hand, multiple
studies have shown that CAS is not as safe as CEA,
especially in symptomatic patients, with the Interna-
tional Carotid Stenting Study (ICSS) being the latest
addition to the mix (94). On the other hand, Carotid
Revascularization Endarterectomy versus Stenting Trial
(CREST) found equal risk of composite primary out-
come of stroke, MI or death in patients undergoing CAS
or CEA (95). The challenge of comparing three different
modalities lie in the practice of modern medicine itself:
the rapid evolution of medical management, CEA and
CAS know how always slanting the risk-benefit ratio in a
different direction. Overall, we have rapidly improving
techniques for effective prevention of stroke from asymp-
tomatic carotid stenosis.
Hyperhomocysteinemia
Elevated plasma levels of homocysteine as a risk factor
for stroke has been traditionally well recognized in athe-
rothrombotic vascular diseases including stroke (96, 97).
It is believed that homocysteine induces endothelial pla-
telet dysfunction, by reducing molecular nitric oxide (98).
Folic acid and cobalamin have been shown to effectively
reduce elevated homocysteine levels, however, clinical
trials have failed to show that this translates into better
cardiovascular or stroke outcomes (99–102). Inflamma-
tion markers seem to be unaffected by lowering homo-
cysteine in secondary stroke prevention, (103) although
it may have a role in patients with genetic predisposition
to hyperhomocysteinemia or those who lack proper die-
tary folate intake.
Lifestyle Modification
Cigarette smoking is a well-established and modifiable
risk factor for both ischemic and hemorrhagic strokes
(104, 105). Several meta-analysis have established ciga-
rette smoking to impart a 2-fold increase in the risk of IS
an 3-fold increase of subarachnoid hemorrhages (106,
107). The most effective preventive measure is to not
smoke or be exposed to smoke. Although quitting smok-
ing is difficult to achieve, it does carry significant bene-
fits, with rapid reduction in the risk of stroke within
several years of cessation (108).
Alcohol consumption has been shown to have to have a
J-shaped relation to risk of stroke, with light to moderate
consumption (=1 drink a day for women and = 2 drinks
a day for man) decreasing the risk of stroke to 0.3 to 0.5,
but the risk increasing to 2 for heavier alcohol use (=3
drinks) a day (109–111). The relative risk is always in-
creased for hemorrhagic strokes, regardless of the amount
consumed. Alcohol in light to moderate quantities in-
creases HDL cholesterol, reduces platelet aggregation
and lowers fibrinogen levels, while heavier use can lead
to hypertension, hypercoaguability and atrial fibrillation
(112). Alcohol consumption should not be advocated as a
way to prevent stroke, however, as alcoholism is a major
public health problem and the risks of excessive intake
remain great.
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Abuse of illicit drugs such as cocaine in its various
forms, heroin and amphetamines are associated with
increased risk of both ischemic and hemorrhagic strokes
by elevating the blood pressure and platelet aggregation,
and inducing vasospasm and cardiac arrhythmias (113).
Diet has been associated with the risk of stroke, with
increased fruit and vegetable consumption having an
inverse relationship to the risk of stroke in a dose-res-
ponse manner (114, 115): for example, for each serving
per day increase in fruit or vegetable intake, the risk of
stroke was reduced by 6% in one study (116). Research
has shown that reducing salt intake improves cardio-
vascular and cerebrovascular health, although a recent
review found no relation to salt intake and CHD mor-
bidity and mortality (117).
Physical inactivity is another modifiable risk factor of
stroke (118). Physical activity has been shown to be bene-
ficial in a dose-response pattern with more intensive
physical activity providing greater benefits than light to
moderate activity. The protective effects of physical acti-
vity are likely derived from lowering of body weight and
BP and better glycemic control (119).
Obesity and body mass index (BMI) are risk factors for
stroke, with associations to hypertension, dyslipidemia
and glucose intolerance (120, 121). An obesity epidemic
has been sweeping developed countries as well as develop-
ing nations such as India and China. The prevalence of
metabolic syndrome worldwide, an entity that encom-
passes several stroke risk factors, was alarmingly high a
decade ago (24–50%) (122). and given the recent trends
is likely to have increased since then. Although no trials
linking weight loss to the risk of stroke exist, evidence
exists that losing weight reduces the presence of risk
factors that cause stroke: in one meta-analysis an average
weight loss of 5.1 kg reduced the systolic BP by 3.6–4.4
mmHg (123). Diet and exercise which are discussed
above can be effective in controlling this modifiable risk
factor.
Obstructive Sleep Apnea
Sleep related breathing disorders are common in pa-
tients with established CVD. Habitual snoring and ob-
structive sleep apnea (OSA) have been shown to be inde-
pendently associated with stroke and snoring has been
strongly associated with vascular events during sleep (124,
125). A recent-meta-analysis of 29 studies has shown that
up to three-quarters of all patients have OSA, with the
highest incidence of stroke occurring in patients with
cryptogenic stroke, possibly establishing OSA an under-
-recognized stroke risk factor (126). Hypoxemia, noc-
turnal hypertension and sympathetic surges have been
postulated as some of many contributors to stroke in
OSA patients. Decreased cerebral blood flow and im-
paired vasomotor reactivity has been observed even when
the patients with OSA are not sleeping (127). Treatments
with continuous positive airway pressure (CPAP) are
non-invasive, and effective in reducing the risk of car-
diovascular events and BP (128, 129). Further studies of
OSA and other sleep disorders are on-going and may
yield novels strategies and approaches in stroke preven-
tion.
Aspirin for Primary Stroke Prevention
Aspirin has been shown as a well-established medi-
cation for primary stroke prevention. A recent meta-
-analysis showed a 32% reduction in MI in men but not
women and a 17% reduction of the risk of stroke in
women, but not men (130). It is not clear why the sex
difference exists, as the platelets seem to be inhibited
equally in either sex, and no gender disparity was iden-
tified in studies in secondary prevention. A trial among
diabetics with a history of atherosclerotic disease found
Aspirin had no statistically significant effect on the rate of
cerebrovascular events (131). Current guidelines indi-
cate low-dose aspirin for women for whom the benefits
may outweigh the risks and for patients with high CHD
risk factors, but not for those at low risk or diabetics
(132).
Genetics of Stroke
Stroke is a complex and multi-factorial disease caused
by the combination of vascular risk factors, environment,
and genetic factors. Recently, the scientific community
put a great effort in understanding the genetic impact to
the risk of stroke (133). Several epidemiological studies
in families and twins have revealed a genetic component
to stroke risk (134). and experimental and clinical re-
search using novel technologies have identified several
genes directly or indirectly implicated in the mechanisms
leading to stroke (135). The genetic contribution seems
to be stronger in stroke patients younger than 70 years
than in those who are older (136, 137).
The strongest associations have been found between
stroke and single nucleotide polymorphisms (SNPs) in
genes involved in inflammation, renin-angiotensin sys-
tem, atherosclerosis, lipid metabolism, and obesity (133).
However, few of these associations have been consis-
tently replicated (138). The innovation of a Genome-
-wide association study (GWAS) has allowed for identifi-
cation of novel genetic loci without a specific hypothesis
implicating a particular molecular pathway. The first
GWAS for IS was conducted using more than 400,000
unique SNPs in a cohort of 249 patients with IS and 268
neurologically normal controls (139). However, these
data did not reveal any single locus conferring a large
effect on IS risk. Other IS GWASs have been conducted
using a meta-analysis approach combining large popu-
lations such as CHARGE (Cohorts for Heart and Aging
Research in Genomic Epidemiology), (140) which con-
sists of 4 prospective epidemiological cohorts of nearly
19,600 subjects with 1,544 incident strokes. In CHARGE,
2 SNPs were identified on chromosome (ch) 12, in the
region of 12p13, and replication was obtained for one
(rs12425791 SNP; the hazard ratio 1.3 for all stroke, and
1.0 for IS). A large International Stroke Genetic Consor-
tium and the NINDS SiGN (Stroke Genetic Network) is
currently conducting a GWAS of over 15,000 IS patients
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and 10,000 controls and expected to have the results
available within a year.
Since stroke is a complex disease probably related to
multiple genetic loci and the interaction of environment
and heredity, the study of the precursors of this complex
phenotype may be more rewarding. For example, the
intermediate phenotypes as markers of subclinical disea-
se such as cIMT, carotid plaque, arterial stiffness, and left
ventricular mass; may be more helpful in identifying
genes related to atherosclerosis and stroke (133). The
genetic research of stroke may greatly enhance our know-
ledge of this complex diseases. It may contribute to the
discovery of new stroke biomarkers, which ultimatelly
may be included in the stroke prevention, diagnosis, and
treatment decisions.
CONCLUSION
Stroke remains a devastating and prevalent world-
-wide disease. The past several decades of research have
also shown it to be a partially-preventable one, with
many risk factors, strategies, and treatments identified,
carefully evaluated and studied. A healthy diet and active
lifestyle, careful control of modifiable stroke risk factors
and access to regular health care are the keys to a success-
ful stroke prevention strategy on both an individual and a
public health level.
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